![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Hoybye, Charlotte; Beck-Peccoz, Paolo; Murray, Robert D.; Simsek, Suat; Stalla, Guenter; Strasburger, Christian J.; Urosevic, Dragan; Zouater, Hichem und Johannsson, Gudmundur
(2021):
Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
In: Pituitary, Bd. 24, Nr. 4: S. 622-629
Pfaeffle, Roland; Bidlingmaier, Martin; Kreitschmann-Andermahr, Ilonka; Land, Christof; Partsch, Carl Joachim; Schwab, Karl Otfried; Sommer, Heide; Backeljauw, Philippe; Kanumakala, Shankar; Loche, Sandro; Zouater, Hichem und Strasburger, Christian J.
(2020):
Safety and Effectiveness of Omnitrope (R), a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
In: Hormone Research in Paediatrics, Bd. 93, Nr. 3: S. 154-163
Beck-Peccoz, Paolo; Hoybye, Charlotte; Murray, Robert D.; Simsek, Suat; Zabransky, Markus; Zouater, Hichem und Stalla, Günter K.
(2020):
Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(R)): data from the PATRO Adults study.
In: Therapeutic Advances in Endocrinology and Metabolism, Bd. 11: S. 1-12
[PDF, 114kB]
Hoybye, Charlotte; Beck-Peccoz, Paolo; Simsek, Suat; Zabransky, Markus; Zouater, Hichem; Stalla, Guenter und Murray, Robert D.
(2020):
Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs.
In: Expert Opinion on Drug Safety, Bd. 19, Nr. 12: S. 1539-1548
Beck-Peccoz, Paolo; Hoybye, Charlotte; Murray, Robert D.; Simsek, Suat; Zabransky, Markus; Zouater, Hichem und Stalla, Guenter
(2019):
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope (R)): data from an observational, longitudinal study.
In: BMC Endocrine Disorders, Bd. 19, Nr. 1, 138